MeiraGTx Holdings plc (MGTX)
Develops gene therapies to treat inherited eye diseases and neurological disorders.
$11.82-0.04%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+54.5%
The outlook
MGTX is trading above both its 50- and 200-day moving averages, positioning it in the upper half of its 52-week range. Analyst price targets average around 140% above the current price, suggesting substantial upside from this vantage point. The stock's technical setup leans bullish relative to recent trading patterns.
What’s behind the score
Price trendAbove its 50- & 200-day averages
52-week range60% of the way from its 52-week low to high
Price targetAvg target +140% vs current price
Analyst price target
~12-month · 8 analysts$28.38average target+140.1% vs now
Now $11.82
Low $19.00High $50.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$1.09B
52-wk high
$15.35
52-wk low
$6.62
50-day avg
$11.15
200-day avg
$9.01
Trailing P/E
—